PharmSource is pleased to announce the publication of our new report, The Market for Analytical Testing and Development Services. The report presents the findings of our extensive effort to model expenditures on GMP analytical development and testing in both the clinical and commercial phases and to understand the factors that will drive outsourcing of analytical activities over the next five years.
The heart of the study is our model of spending for CMC development, including API process development, formulation, CTM manufacture and associated analytical testing. We have constructed a model driven by the new product pipeline and the outsourcing behavior of the major end-customer segments. A separate model breaks down spending for analytical testing of commercial products.
Based on our model, PharmSource estimates industry spending for CMC development services at about USD 9.3 billion, divided almost equally among process and formulation development, analytical development and testing, and CTM manufacture. We estimate that as much as two-thirds of that spending is already outsourced, either to CDMOs or dedicated contract labs. Growth in the market will be constrained by a likely shrinkage in the development pipeline, and North American and European contractors will be challenged by merging competition from Asia.
For more information, please download a PDF brochure and order form for this Special Report.